Cocrystal Pharma Inc (COCP) stock has risen 48.24% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With COCP Stock Today?
Cocrystal Pharma Inc (COCP) stock is trading at $1.26 as of 2:35 PM on Tuesday, Nov 24, a gain of $0.39, or 44.16% from the previous closing price of $0.87. The stock has traded between $0.79 and $1.43 so far today. Volume today is above average. So far 19,188,952 shares have traded compared to average volume of 685,259 shares.
To see InvestorsObserver's Sentiment Score for Cocrystal Pharma Inc click here.
More About Cocrystal Pharma Inc
Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.
Click Here to get the full Stock Score Report on Cocrystal Pharma Inc (COCP) Stock.
